Hepatitis C prevalence in the psychiatric setting: cost-effectiveness of scaling-up screening and direct-acting antiviral therapy

Girardin, François; Painter, Chris; Hearmon, Natalie; Eddowes, Lucy; Kaiser, Stefan; Negro, Francesco; Vernaz-Hegi, Nathalie

doi:10.1016/j.jhepr.2021.100279

Scientific article

English

Hepatitis C prevalence in the psychiatric setting: cost-effectiveness of scaling-up screening and direct-acting antiviral therapy

ContributorsGirardin, François; Painter, Chris; Hearmon, Natalie; Eddowes, Lucy; Kaiser, Stefan; Negro, Francesco; Vernaz-Hegi, Nathalie

Published inJHEP Reports : Innovation in Hepatology, vol. 3, no. 3, 100279

Publication date2021

Abstract

Patients hospitalised because of mental illness often have risk factors for contracting HCV. Scaling-up HCV screening for all psychiatric inpatients as a case-detection strategy for viral elimination is underexplored. This study aimed to evaluate the cost-effectiveness of scaling-up HCV screening and treatment for psychiatry hospital admissions in Switzerland vs. the current standard-of-care risk-based approach, where only those with a history of substance misuse disorder are offered testing.

Keywords

Cost-effectiveness model
DAA, direct-acting antiviral
Direct-acting antiviral agents
Hepatitis C infection
ICER, Incremental cost-effectiveness ratio
NMB, net monetary benefit
PMI, patients with mental illnesses
PSA, probabilistic sensitivity analysis
Psychiatric disorder
QALY, quality-adjusted life-year
Screening strategy
WTP, willingness-to-pay

Affiliation entities

Research groups

Citation (ISO format)

GIRARDIN, François et al. Hepatitis C prevalence in the psychiatric setting: cost-effectiveness of scaling-up screening and direct-acting antiviral therapy. In: JHEP Reports : Innovation in Hepatology, 2021, vol. 3, n° 3, p. 100279. doi: 10.1016/j.jhepr.2021.100279